Tomatoes Recalled in 14 States as FDA Sets Highest Risk Level
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Two separate recalls have been classified as Class I, the most serious warning level, by the Food and Drug Administration (FDA) because of potential salmonella contamination in raw tomato products distributed across multiple U.S. states.
The ongoing recalls, both initiated voluntarily by the distributing firms, involve tomatoes produced by Williams Farms Repack LLC under the brand name Hanshaw & Capling Farm (or H&C Farms) in Immokalee, Florida, and by Ray & Mascari Inc. of Indianapolis.
Newsweek has contacted Ray & Mascari Inc. for comment via email outside regular working hours and Williams Farms Repack LLC via phone.
Why It Matters
The recalls affect large quantities of tomatoes distributed across a number of states and include both retail and bulk packaging. The potential contamination with salmonella—a bacteria that can cause serious and sometimes fatal infections in young children, elderly people and those with weakened immune systems—determines the high level of risk to consumers associated with the recall.
Healthy persons infected with salmonella often experience fever, diarrhea (which may be bloody), nausea, vomiting and abdominal pain. In rare circumstances, infection with salmonella can result in the organism getting into the bloodstream and producing more severe illnesses, such as arterial infections (i.e., infected aneurysms), endocarditis and arthritis.
A stock image of ripe tomatoes.
A stock image of ripe tomatoes.
Winfried Rothermel/dpa via AP
What To Know
The recall from Williams Farms Repack involves 3,651 boxes of "H&C Farms Raw Premium Tomatoes, Naturally Grown from Seed" packaged in various sizes ranging from jumbo to 6x7, with all requiring refrigeration.
The affected lot is marked as 098 14TO3-1. The product was distributed in Texas, Illinois, Wisconsin, South Carolina, Florida, Tennessee, Indiana and Massachusetts.
The recall was initiated on April 29 and classified by the FDA on May 13.
Separately, Ray & Mascari issued a recall of 510 cases of vine ripe tomatoes. The products were contained in clamshell packages and several bulk packaging sizes. Affected lot numbers range from RM 250420 to RM 250427.
The tomatoes were distributed across Indiana, Kentucky, Massachusetts, Maryland, Michigan, North Carolina, Ohio, Pennsylvania and Wisconsin.
The recall was initiated on April 30 and classified by the FDA on May 13.
While no illnesses have been publicly linked to these products, the Class I designation indicates that use of or exposure to them may cause serious adverse health consequences or death.
What People Are Saying
The FDA said on its website: "Most people infected with Salmonella will begin to develop symptoms 12 to 72 hours after infection. The illness, salmonellosis, usually lasts four to seven days and most people recover without treatment. Most people with salmonellosis develop diarrhea, fever, and abdominal cramps.
"More severe cases of salmonellosis may include a high fever, aches, headaches, lethargy, a rash, blood in the urine or stool, and in some cases may become fatal. The U.S. Centers for Disease Control and Prevention estimated that approximately 450 persons in the United States die each year from acute salmonellosis.
"Due to the range in severity of illness, people should consult their healthcare provider if they suspect that they have developed symptoms that resemble a Salmonella infection."
What Happens Next
Both recalls remain ongoing. Consumers are advised to check for the listed lot numbers and discard any affected products.
Consumers who have purchased the Ray & Mascari products and have questions or reports of any illness may contact the company at 1-317-637-0234 between Monday and Saturday from 6 a.m. to 5 p.m. ET. Consumers who purchased the Williams Farm Repack products may contact the company at 843-866-7707 or 843-599-5154 between Monday and Friday from 8 a.m. to 5 p.m. ET.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
34 minutes ago
- Bloomberg
FDA Pauses Trials of Gilead HIV Combination After Safety Signal
Gilead Sciences Inc. said federal regulators had placed on hold trials of a new experimental once-weekly HIV drug combination therapy after white blood cell counts dropped in some of the patients. The studies were testing two experimental HIV drugs, GS-1720 and GS-4182, when given together. Gilead said the Food and Drug Administration paused the trials due to a ' safety signal ' triggered by a decrease in lymphocyte levels in some patients given the therapy. Lymphocytes are a type of white blood cell that play a critical role in the immune system's ability to fight infections.
Medscape
39 minutes ago
- Medscape
Insmed's Drug for Rare Lung Disease Meets Main Goal in Mid-stage Trial
(Reuters) -Insmed said on Tuesday that its experimental drug significantly reduced blood pressure in the lungs and improved exercise capacity in patients in a mid-stage study, sending shares of the company up 26% in premarket trading. The drug, treprostinil palmitil, is a once-daily therapy that is inhaled through a device. The 102-patient study found that the drug helped reduce blood pressure in the patients' lungs by 35%, compared with a placebo. It also helped improve the patients' ability to walk by an average of 35.5 meters and reduced levels of a protein associated with heart stress by 60%. The company plans to discuss the trial data with the U.S. Food and Drug Administration and initiate a late-stage trial for the drug in patients with pulmonary arterial hypertension (PAH) — a rare disease caused by a constriction of arteries in the lungs, leading to high blood pressure - in early 2026. Insmed also plans to start a separate late-stage trial for the drug in patients with pulmonary hypertension associated with interstitial lung disease - a condition where lung scarring leads to high blood pressure in the lung arteries - before the end of 2025. Current treatment options available to treat PAH are Merck's injectable Winrevair and Liquidia's inhaled Yutrepia. (Reporting by Kamal Choudhury in Bengaluru; Editing by Maju Samuel) Reuters Health Information © 2025 Reuters Ltd.
Newsweek
an hour ago
- Newsweek
Honey Recall Map Shows Warnings Issued to Customers in 7 States
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The Food and Drug Administration (FDA) has announced its classification of a recall of certain Comvita honey products, affecting seven states. Comvita, a California-based company, recalled three of its manuka honey products last month as the induction seal was not properly fitted, meaning the product was leaking on the packaging. Newsweek has contacted Comvita outside of regular working hours via email for comment. File photo: a teaspoon with a jar full of honey. File photo: a teaspoon with a jar full of honey. Oliver Berg/dpa via AP Why It Matters Maintaining packaging standards is important as it can make consumers feel more assured that companies have followed regulatory guidance more closely, and ensured their products are properly manufactured and controlled. Given that many Americans are concerned about food safety and food recalls, maintaining standards and regulations are even more important if brands want to establish consumer trust. What To Know The affected products include: Comvita's Manuka Honey + Lion's Mane for Focus (355g), with lot codes 34828522 and 34835584, and expiration dates of January 21, 2026 and February 21, 2026 respectively Comvita's Manuka Honey + Cordyceps for Energy (355g) with lot codes 34828523 and 34835585, and expiration dates of January 22, 2026 and February 25, 2026 respectively Comvita's Manuka Honey + Reishi (355g) with lot codes 34828521 and 34835574, and expiration dates of January 21, 2026 and February 24, 2026 respectively There were 2,730 units sold of each product, to various states including Colorado, Arizona, Texas, Maryland, Florida, California, and Georgia. Comvita initiated the recall on May 23, and the FDA announced its classification of the recall on June 9. The FDA classification of the recall was a Class II, meaning it is a situation "in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote." What People Are Saying Professor Byron Chaves, a professor and food safety extension specialist in the department of Food Science and Technology at the University of Nebraska-Lincoln, told Newsweek: "An induction seal is a protective seal commonly found on food containers, like jars or bottles, just under the cap. It's created using heat to attach a foil liner to the container's opening, forming a tight, tamper-evident seal. This helps prevent leaks, keeps the product fresh, and shows if the package has been opened." He added: "If an induction seal isn't properly applied, it can lead to leaks, contamination, and reduced shelf life. It also means the package may not show evident signs of tampering, which can raise safety concerns. In some cases, it could lead to regulatory issues or loss of consumer trust if the product appears unsafe or poorly sealed." What Happens Next Consumers are advised not to consume the affected products and return them to the place of purchase for a refund. As of June 9, the recall remains ongoing. The FDA did not specify if any illnesses had been reported in relation to the recall.
